SCHEMBL1721285

SCHEMBL1721285

CCCCOC(=O)NC(CC(=O)OC)c1ccc(O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.47
SMN1; SMN2 Q16637 8/20 0.47
NPC1 O15118 6/20 0.47
RAB9A P51151 6/20 0.47
HPGD P15428 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPK1 P28482 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
LMNA P02545 2/20 0.47
ESR1 P03372 2/20 0.47
CYP2D6 P10635 1/20 0.47
TSHR P16473 1/20 0.47
NR1H2 P55055 1/20 0.47
RNASEL Q05823 1/20 0.47
CASP1 P29466 1/20 0.41
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
ESR2 Q92731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4096169 0.89 POLB (0.51) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL4385673 0.88 SMN1; SMN2 (0.51) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3996623 0.85 FAAH (0.55) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3821977 0.84 MAPT (0.49) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL8138065 0.84 SMN1; SMN2 (0.49) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6831614 0.83 NPC1 (0.47) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL539214 0.83 HTT (0.46) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6190128 0.82 FAAH (0.48) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL1721708 0.82 FAAH (0.43) FAAHSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL15145212 0.81 SMN1; SMN2 (0.48) FAAHSMN1; SMN2NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406247-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2012-01-18 EP disclosed
WO-2011094890-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2011-08-11 WO disclosed
EP-2200609-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2010-06-30 EP disclosed
WO-2009034388-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2009-03-19 WO disclosed
EP-1701933-A1 NOVEL COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2006-09-20 EP disclosed
WO-2005061440-A1 NOVEL COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2005-07-07 WO disclosed